<DOC>
	<DOCNO>NCT00084513</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Imatinib mesylate may stop growth tumor cell block enzymes necessary growth stop blood flow tumor . Giving trastuzumab together imatinib mesylate may kill tumor cell . PURPOSE : This phase I trial study side effect best dose imatinib mesylate give together trastuzumab treat patient recurrent metastatic HER2/neu-expressing ( produce ) cancer .</brief_summary>
	<brief_title>Trastuzumab Imatinib Mesylate Treating Patients With Recurrent Metastatic HER2/Neu-Expressing Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose imatinib mesylate administer trastuzumab ( Herceptin® ) patient recurrent metastatic HER2/neu-overexpressing cancer . - Determine response patient treat regimen . Secondary - Correlate number circulate tumor cell radiographic image patient treated regimen . OUTLINE : This dose-escalation study imatinib mesylate . Patients receive trastuzumab ( Herceptin® ) IV 90 minute day 1 oral imatinib mesylate twice daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos imatinib mesylate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 9-18 patient accrue study .</detailed_description>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm cancer overexpresses HER2/neu , measure 3+ immunohistochemistry positive fluorescence situ hybridization Recurrent metastatic disease Meets 1 follow criterion measurable evaluable disease : Unidimensionally measurable disease least 20 mm conventional technique OR least 10 mm spiral CT scan Evaluable disease , define lesion physical examination image study assess change size clearly measure 1 dimension ( e.g. , pleural effusion , ascites , bone disease ) No carcinomatous meningitis untreated/uncontrolled metastatic brain parenchymal disease Prior control brain parenchymal disease allow provide least 8 week since prior therapy AND symptomatic progression corticosteroid PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic ALT AST ≤ 2.0 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.0 time ULN Bilirubin ≤ 1.3 mg/dL No known chronic liver disease ( i.e. , chronic active hepatitis cirrhosis ) Renal Creatinine ≤ 2.0 mg/dL Cardiovascular Ejection fraction ≥ low limit normal MUGA No uncontrolled significant cardiovascular disease No myocardial infarction within past 6 month No ischemic heart disease require medication No congestive heart failure Pulmonary No uncontrolled significant pulmonary disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month study participation No active unresolved infection PRIOR CONCURRENT THERAPY : Biologic therapy Prior trastuzumab ( Herceptin® ) allow No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) support blood count No concurrent anticancer biologic agent Chemotherapy Prior chemotherapy metastatic disease allow At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover No concurrent anticancer chemotherapy Endocrine therapy See Disease Characteristics Radiotherapy At least 4 week since prior radiotherapy recover Surgery More 2 week since prior major surgery Other At least 7 day since prior antibiotic No concurrent parenteral antibiotic No concurrent anticancer agents No concurrent investigational drug No concurrent therapeutic anticoagulation warfarin Concurrent minidose warfarin ( 1 mg/day ) prophylaxis central venous catheter thrombosis allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>